FDA Orphan Drug Designation granted to aldesleukin for treatment of amyotrophic lateral sclerosis (ALS)

Aldesleukin is an immunomodulatory agent that has been shown to enhance regulatory T-cells function in patients with ALS, whom have decreased levels, which are associated with increased disease severity. It is currently licensed in the UK for treatment of metastatic renal cancer.

Source:

PharmaTimes